ID: ALA2151735

Max Phase: Preclinical

Molecular Formula: C27H35N5O5

Molecular Weight: 509.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N(C)[C@H](C)C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O

Standard InChI:  InChI=1S/C27H35N5O5/c1-15-9-20(33)10-16(2)21(15)12-22(28)26(36)31(4)17(3)25(35)30-23-11-18-7-5-6-8-19(18)13-32(27(23)37)14-24(29)34/h5-10,17,22-23,33H,11-14,28H2,1-4H3,(H2,29,34)(H,30,35)/t17-,22+,23+/m1/s1

Standard InChI Key:  XIEQJBFSORDBIQ-VSDWSMLSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 509.61

Molecular Weight (Monoisotopic): 509.2638

AlogP: 0.28

#Rotatable Bonds: 8

Polar Surface Area: 159.06

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.75

CX Basic pKa: 7.75

CX LogP: 0.67

CX LogD: 0.16

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.40

Np Likeness Score: -0.07

References

1. Vandormael B, Fourla DD, Gramowski-Voss A, Kosson P, Weiss DG, Schröder OH, Lipkowski A, Georgoussi Z, Tourwé D..  (2011)  Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties.,  54  (22): [PMID:21978284] [10.1021/jm200894e]

Source

Source(1):

• Scientific Literature